VONTOBEL FINANCIAL PRODUCTS GMBH | Real-time Boerse Frankfurt Warrants 11:05:20 2024-06-07 am EDT | ||
| 102 EUR | -0.21% |
|
| Current month | +0.30% | ||
| 1 month | +1.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 102 | -0.21% |
| 24-06-06 | 102.2 | +0.18% |
| 24-06-05 | 102 | -0.01% |
| 24-06-04 | 102 | +0.11% |
| 24-06-03 | 101.9 | +0.03% |
Real-time Boerse Frankfurt Warrants
Last update June 07, 2024 at 11:05 am EDT
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM7ECJ |
| ISIN | DE000VM7ECJ2 |
| Date issued | 2024-01-22 |
| Strike | 726.6 kr |
| Maturity | 2024-12-20 (196 Days) |
| Parity | 0.73 : 1 |
| Emission price | 100 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 102.5 € |
|---|---|
| Lowest since issue | 98.67 € |
| Spread | 5 € |
| Spread % | 0.49% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
973.3
DKK
Average target price
920.8
DKK
Spread / Average Target
-5.40%
- Stock Market
- Certificates
- Certificat
